The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 16, 2024
Filed:
Aug. 16, 2021
Applicant:
Mission Therapeutics Limited, Cambridge, GB;
Inventors:
Assignee:
Mission Therapeutics Limited, Cambridge, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 201/00 (2006.01); A61K 31/4025 (2006.01); A61K 31/407 (2006.01); A61K 31/4725 (2006.01); A61P 3/00 (2006.01); A61P 3/10 (2006.01); A61P 9/00 (2006.01); A61P 19/02 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 43/00 (2006.01); C07D 207/09 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61P 25/00 (2018.01); A61P 35/04 (2018.01); C07D 403/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the Invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, X, L and A are as defined herein.